Key result
Angiotensin II receptor blockers had a neutral effect on cancer incidence compared to placebo without background ACEI use (RR 1.08; 95% CI 1.00-1.18; P=0.05).
Why the study?
Do Angiotensin II receptor blockers (ARB) increase cancer incidence in patients compared to placebo or ACEI?
Population
19 RCTs including 148,334 patients with at least 12 months of follow-up data
Comparison
Angiotensin II receptor blockers alone or in… vs Placebo alone, ACEI alone, placebo plus partial…
Design
Meta-analysis
Follow-up
at least 12 months
Authors
Loading...
ARBs show no excess cancer risk across ACEI backgrounds; reinforces RCT meta-analyses supporting cardiovascular use without oncologic concern.
Meta-Analysis (n=148,334)
Do Angiotensin II receptor blockers (ARB) increase cancer incidence in patients compared to placebo or ACEI?
Relative Risk: 1.08 (95% CI 1–1.18)
p-value: p=0.05
This meta-analysis demonstrates that ARBs have a neutral effect on cancer incidence, regardless of background ACEI use.
Zhao et al. (2016) reported a meta-analysis. Angiotensin II receptor blockers (ARB) vs. Placebo or ACE inhibitors (ACEI) was evaluated on Cancer incidence (RR 1.08, 95% CI 1.00-1.18, p=0.05). Angiotensin II receptor blockers had a neutral effect on cancer incidence compared to placebo without background ACEI use (RR 1.08; 95% CI 1.00-1.18; P=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: